Deadline
Passed
Lead Plaintiff Deadline: February 14, 2020
(1) Mylan’s Morgantown facility was in significant violation of the FDA’s Current Good Manufacturing Practice regulations; (2) Mylan would need to engage in a massive restructuring and remediation program; (3) Mylan’s North American Segment would be substantially impacted by said program, which would in turn materially impact Mylan’s financial health; (3) Mylan lacked effective internal control over financial reporting; and (4) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.